GlassScriptPhysician profile
Eva Raisor
NPI 1528304300
$5,272.43
in general payments reported to CMS, 2019-2025
20 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $370 · 2023: $1,539 · 2024: $1,469 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,694 · Education: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,694.36 |
| Education | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,517.30 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $950.88 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $726.92 | 2023-2025 | |
| Glaxosmithkline, LLC. | $493.08 | 2022-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Csl Behring | $359.62 | 2023-2025 | Haegarda, Andembry, Hizentra |
| Amgen INC. | $158.90 | 2023-2025 | Tezspire, Actimmune |
| Biocryst US Sales Co., LLC | $134.98 | 2023-2025 | Orladeyo |
| Pfizer INC. | $127.62 | 2024 | |
| Novartis Pharmaceuticals Corporation | $123.85 | 2025 | |
| Kaleo, INC. | $110.25 | 2023-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $110.06 | 2025 | Neffy |
| Blueprint Medicines Corporation | $97.91 | 2024-2025 | Ayvakit |
| Genentech USA, INC. | $94.01 | 2023-2025 | Xolair |
| Optinose US, INC. | $84.68 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.36 | 2024-2025 | Hyqvia, Eohilia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $42.42 | 2025 | Panzyga |
| Organon LLC | $31.49 | 2025 | |
| Ionis Pharmaceuticals, INC. | $26.02 | 2025 | Dawnzera |
| Lilly USA, LLC | $21.58 | 2024 | Ebglyss |
| Alk-Abello, INC | $15.50 | 2023 | Ragwitek, Odactra, Grastek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Raisor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.